Purpose: Microbicide effectiveness for HIV/STI prevention may require specific timing of application in relationship to coitus. We examined actual timing of use of a microbicide surrogate (vaginal moisturizer [VM]) compared to assigned timing condition among young women.
post-coitus). The 1-hour pre-coitus and the 10-minute pre-coitus groups both had significantly smaller standard deviations than the post-coital group (t = 4.45 and 2.22, respectively). In the 10 minute post-coital group 65% (286/443) of VM use was pre-coital and 18% (78/443) was 30 or more minutes post-coital. The VM was used within 30 minutes before coitus in about half of the events (n = 513); in the majority of these events women reported the VM was very easy to use (n = 365); somewhat messy (n = 316); that they were very wet during sex (n = 422); and that the sex was very good (n = 400). In addition, women reported that their partners liked using the VM (n = 220).
Conclusions:
Overall there was tremendous variation in timing of VM application during the 59% of coital events in which it was used. Although median time values of actual VM use accurately reflected assigned timing condition in the pre-coital groups, there was substantial deviation in application time across the three timing conditions with significantly greater variability in the post-coital group. While VM use was positively rated in terms of ease of use and feeling during coitus; these results have implications for behavioral challenges related to specific timing requirements for microbicide application, especially for young women. For instance, it is often difficult to accurately estimate when coitus will occur, making pre-coital application difficult while post-coital application necessitates having the microbicide accessible. These findings suggest that targeted educational efforts will need to be directed at young people, including messages about the increased comfort with use, in order to increase the likelihood that future microbicides will be used at appropriate times to optimize HIV/STI prevention effectiveness.
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